Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

SAN DIEGO, May 28, 2024 -- Gyre Therapeutics , a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today...

Related Keywords

United States ,San Diego ,California ,London ,City Of ,United Kingdom ,Chan Ying ,Stephen Jasper ,Exchange Commission ,Gyre Pharmaceuticals ,London Stock Exchange Group ,Russell Indexes ,Chief Executive Officer ,London Stock Exchange ,Private Securities Litigation Reform Act ,Annual Report ,